GlassScriptPhysician profile
Rene Alberto Castillo
NPI 1134186166
$1,000.70
in general payments reported to CMS, 2019-2025
19 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2021: $25.67 · 2022: $216 · 2023: $239 · 2024: $150 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536 · Education: $55.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.92 |
| Education | $55.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $260.70 | 2019-2025 | Tecvayli, Darzalex |
| Stryker Corporation | $169.72 | 2023 | Mako |
| Celgene Corporation | $99.72 | 2022-2025 | Reblozyl |
| Janssen Pharmaceuticals, INC | $75.94 | 2023-2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $59.28 | 2024-2025 | |
| Pfizer INC. | $51.52 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $43.65 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $35.25 | 2021-2024 | Calquence |
| Glaxosmithkline, LLC. | $29.92 | 2025 | Jemperli, Blenrep, Ojjaara |
| Seagen INC. | $23.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.85 | 2022 | |
| Boston Scientific Corporation | $19.81 | 2022 | |
| Daiichi Sankyo INC. | $19.19 | 2025 | Enhertu |
| Servier Pharmaceuticals LLC | $19.04 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.82 | 2022 | |
| Puma Biotechnology, INC. | $14.99 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Exelixis INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.